IPP Bureau
Lonza outlines strategy, new organizational structure and guidance
By IPP Bureau - December 12, 2024
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion
By IPP Bureau - December 12, 2024
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
By IPP Bureau - December 12, 2024
First and only PARP inhibitor to improve overall survival in early breast cancer
AbbVie completes acquisition of Aliada Therapeutics
By IPP Bureau - December 12, 2024
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Gland Pharma receives approval for phytonadione injection emulsion
By IPP Bureau - December 12, 2024
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
By IPP Bureau - December 12, 2024
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Briefs: Alembic Pharmaceuticals and Veerhealth Care
By IPP Bureau - December 12, 2024
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Genpharmasec enters into supper stockist agreement with Amneal Healthcare
By IPP Bureau - December 11, 2024
Dr. Morepen introduces ‘LightLife’ to long-lasting weight management
By IPP Bureau - December 11, 2024
Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
By IPP Bureau - December 11, 2024
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
By IPP Bureau - December 10, 2024
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities
By IPP Bureau - December 10, 2024
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients
By IPP Bureau - December 09, 2024
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma
By IPP Bureau - December 09, 2024
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Roche’s Polivy combination therapy sets new standard of care for untreated aggressive lymphoma
By IPP Bureau - December 09, 2024
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
